We are live on ! Find out more
KAPA icon

Kairos Pharma
KAPA

5 hedge funds and large institutions have $618K invested in Kairos Pharma in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,150% more capital inflows, than outflows

Capital inflows: $603K | Capital outflows: $48.2K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

150% more funds holding

Funds holding: 2 → 5 (+3)

2.81% more ownership

Funds ownership: 0.35% → 3.16% (+2.8%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UMB Bank
UMB Bank
Missouri
+$569K
2
Citadel Advisors
Citadel Advisors
Florida
+$16.8K
3
UBS Group
UBS Group
Switzerland
+$16.6K
4
Bank of America
Bank of America
North Carolina
+$21

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$29.2K
2
HRT Financial
HRT Financial
New York
-$19K

KAPA Hedge Fund Activity: Q4 2024 in Review

5 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q4 2024, worth a combined $618K — up 783% from $70K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new KAPA positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UMB Bank, opening a new position worth an estimated $569K. The largest seller was Virtu Financial, cutting an estimated $29.2K.

  • 5 institutional investors held Kairos Pharma (KAPA) as of Q4 2024, up from 2 in Q3 2024.
  • Funds reported $618K of Kairos Pharma stock for Q4 2024, up 783% quarter-over-quarter.
  • 4 funds opened new Kairos Pharma positions in Q4 2024 and 1 closed out, a net change of +3 holders.
  • The largest Kairos Pharma buyer in Q4 2024 was UMB Bank, an estimated $569K added.
  • The largest Kairos Pharma seller in Q4 2024 was Virtu Financial, an estimated $29.2K sold.

Based on aggregated 13F filings for Q4 2024.